Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Grand View Research | PRODUCT CODE: 1611243

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1611243

India Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design, By Indication, By Service Type, By Sponsor, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 110 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4950
Printable PDF (5-User License)
USD 5950
Printable PDF (Enterprise License)
USD 7950

Add to Cart

India Clinical Trials Market Growth & Trends:

The India clinical trials market size is estimated to reach USD 2.22 billion by 2030, expanding at a CAGR of 8.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. The globalization of clinical trials, growing disease variation and prevalence in the country, adoption of new technology in clinical research, and increasing R&D promoting outsourcing are the key factors driving the market.

India is populated with 1.3 billion individuals with varying genetic backgrounds and a large treatment-naive patient pool for the development of therapeutics on a range of disease conditions. Furthermore, the economic, environmental, and ecological variations in the 28 states and 8 union territories present the most diverse disease profile. Apart from this, the cost of carrying out clinical trials in India is nearly 40-70% less when compared to that in Europe or the U.S. Thus, the cost efficiency, along with skill sets and ease of doing business, is anticipated to fuel the market growth.

The increasing R&D investments by pharmaceutical and biopharmaceutical companies have led to increased demand for contract research organizations and outsourcing of trials in order to curb the cost. Furthermore, outsourcing enables the drug companies to focus on their core competencies and aids in improving their productivity, thus facilitating the outsourcing of trials in India. The COVID-19 pandemic has improved the market in the country. Several companies globally are conducting clinical trials for COVID-19 vaccines in India. Moreover, government initiatives promoting clinical trials for COVID-19 therapeutics in the country have promoted market growth.

India Clinical Trials Market Report Highlights:

  • By phase, the phase I segment is projected to register the fastest growth rate of 9.7% over the forecast period. This can be attributed to the increasing R&D spending by pharmaceutical and biopharmaceutical companies
  • The interventional trials segment dominated the market with the largest revenue share in 2024, driven by the widespread adoption of interventional trials recognized for their effectiveness in evaluating the safety and efficacy of new drugs and therapies.
  • The oncology segment dominated the market, with the largest revenue share in 2024, and is projected to witness the fastest CAGR over the forecast period
Product Code: GVR-2-68038-676-9

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Phase
    • 1.2.2. Study Design
    • 1.2.3. Indication
    • 1.2.4. Service Type
    • 1.2.5. Sponsor
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. India Clinical Trials Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. India Clinical Trials Market: Phase Business Analysis

  • 4.1. Phase Market Share, 2024 & 2030
  • 4.2. Phase Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Phase, 2018 to 2030 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I Market, 2018 - 2030 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II Market, 2018 - 2030 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III Market, 2018 - 2030 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV Market, 2018 - 2030 (USD Million)

Chapter 5. India Clinical Trials Market: Study Design Business Analysis

  • 5.1. Study Design Market Share, 2024 & 2030
  • 5.2. Study Design Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
  • 5.4. Interventional Trials
    • 5.4.1. Interventional Trials Market, 2018 - 2030 (USD Million)
  • 5.5. Observational Trials
    • 5.5.1. Observational Trials Market, 2018 - 2030 (USD Million)
  • 5.6. Expanded Access Trials
    • 5.6.1. Expanded Access Trials Market, 2018 - 2030 (USD Million)

Chapter 6. India Clinical Trials Market: Indication Business Analysis

  • 6.1. Indication Market Share, 2024 & 2030
  • 6.2. Indication Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 6.4. Autoimmune/Inflammation
    • 6.4.1. Autoimmune/Inflammation Market, 2018 - 2030 (USD Million)
    • 6.4.2. Rheumatoid Arthritis
      • 6.4.2.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
    • 6.4.3. Multiple Sclerosis
      • 6.4.3.1. Multiple Sclerosis Market, 2018 - 2030 (USD Million)
    • 6.4.4. Osteoarthritis
      • 6.4.4.1. Osteoarthritis Market, 2018 - 2030 (USD Million)
    • 6.4.5. Irritable Bowel Syndrome (IBS)
      • 6.4.5.1. Irritable Bowel Syndrome (IBS) Market, 2018 - 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others Market, 2018 - 2030 (USD Million)
  • 6.5. Pain Management
    • 6.5.1. Pain Management Market, 2018 - 2030 (USD Million)
    • 6.5.2. Chronic Pain
      • 6.5.2.1. Chronic Pain Market, 2018 - 2030 (USD Million)
    • 6.5.3. Acute Pain
      • 6.5.3.1. Acute Pain Market, 2018 - 2030 (USD Million)
  • 6.6. Oncology
    • 6.6.1. Oncology Market, 2018 - 2030 (USD Million)
    • 6.6.2. Blood Cancer
      • 6.6.2.1. Blood Cancer Market, 2018 - 2030 (USD Million)
    • 6.6.3. Solid Tumors
      • 6.6.3.1. Solid Tumors Market, 2018 - 2030 (USD Million)
    • 6.6.4. Others
      • 6.6.4.1. Others Market, 2018 - 2030 (USD Million)
  • 6.7. CNS Conditions
    • 6.7.1. CNS Conditions Market, 2018 - 2030 (USD Million)
    • 6.7.2. Epilepsy
      • 6.7.2.1. Epilepsy Market, 2018 - 2030 (USD Million)
    • 6.7.3. Parkinson's Disease (PD)
      • 6.7.3.1. Parkinson's Disease (PD) Market, 2018 - 2030 (USD Million)
    • 6.7.4. Huntington's Disease
      • 6.7.4.1. Huntington's Disease Market, 2018 - 2030 (USD Million)
    • 6.7.5. Stroke
      • 6.7.5.1. Stroke Market, 2018 - 2030 (USD Million)
    • 6.7.6. Traumatic Brain Injury (TBI)
      • 6.7.6.1. Traumatic Brain Injury (TBI) Market, 2018 - 2030 (USD Million)
    • 6.7.7. Amyotrophic Lateral Sclerosis (ALS)
      • 6.7.7.1. Amyotrophic Lateral Sclerosis (ALS) Market, 2018 - 2030 (USD Million)
    • 6.7.8. Muscle Regeneration
      • 6.7.8.1. Muscle Regeneration Market, 2018 - 2030 (USD Million)
    • 6.7.9. Others
      • 6.7.9.1. Others Market, 2018 - 2030 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes Market, 2018 - 2030 (USD Million)
  • 6.9. Obesity
    • 6.9.1. Obesity Market, 2018 - 2030 (USD Million)
  • 6.10. Cardiovascular
    • 6.10.1. Cardiovascular Market, 2018 - 2030 (USD Million)
  • 6.11. Others
    • 6.11.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. India Clinical Trials Market: Service Type Business Analysis

  • 7.1. Service Type Market Share, 2024 & 2030
  • 7.2. Service Type Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Service Type, 2018 to 2030 (USD Million)
  • 7.4. Protocol Designing
    • 7.4.1. Protocol Designing Market, 2018 - 2030 (USD Million)
  • 7.5. Site Identification
    • 7.5.1. Site Identification Market, 2018 - 2030 (USD Million)
  • 7.6. Patient Recruitment
    • 7.6.1. Patient Recruitment Market, 2018 - 2030 (USD Million)
  • 7.7. Laboratory Services
    • 7.7.1. Laboratory Services Market, 2018 - 2030 (USD Million)
  • 7.8. Bioanalytical Testing Services
    • 7.8.1. Bioanalytical Testing Services Market, 2018 - 2030 (USD Million)
  • 7.9. Clinical Trial Data Management Services
    • 7.9.1. Clinical Trial Data Management Services Market, 2018 - 2030 (USD Million)
  • 7.10. Others
    • 7.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. India Clinical Trials Market: Sponsor Business Analysis

  • 8.1. Sponsor Market Share, 2024 & 2030
  • 8.2. Sponsor Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by Sponsor, 2018 to 2030 (USD Million)
  • 8.4. Pharmaceutical & Biopharmaceutical Companies
    • 8.4.1. Pharmaceutical & Biopharmaceutical Companies Market, 2018 - 2030 (USD Million)
  • 8.5. Medical Device Companies
    • 8.5.1. Medical Device Companies Market, 2018 - 2030 (USD Million)
  • 8.6. Others
    • 8.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. IQVIA
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Phase Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Parexel International (MA) Corporation
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Phase Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Thermo Fisher Scientific Inc
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Phase Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Charles River Laboratories
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Phase Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. ICON PLC
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Phase Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Aurigene Oncology
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Phase Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Aragen Life Sciences Ltd
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Phase Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Syneos Health
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Phase Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. SGS Societe Generale de Surveillance SA
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Phase Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Syngene International Limited
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Phase Benchmarking
      • 9.5.10.4. Strategic Initiatives
Product Code: GVR-2-68038-676-9

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. India clinical trials market, by phase, 2018 - 2030 (USD Million)
  • Table 4. India clinical trials market, by study design, 2018 - 2030 (USD Million)
  • Table 5. India clinical trials market, by indication, 2018 - 2030 (USD Million)
  • Table 6. India clinical trials market, by service type, 2018 - 2030 (USD Million)
  • Table 7. India clinical trials market, by sponsor, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 India clinical trials market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Phase outlook (USD Billion)
  • Fig. 10 Transportation mode outlook (USD Billion)
  • Fig. 11 Competitive landscape
  • Fig. 12 India clinical trials market dynamics
  • Fig. 13 India clinical trials market: Porter's five forces analysis
  • Fig. 14 India clinical trials market: PESTLE analysis
  • Fig. 15 India clinical trials market: Phase segment dashboard
  • Fig. 16 India clinical trials market: Phase market share analysis, 2024 & 2030
  • Fig. 17 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 18 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 19 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 20 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 21 India clinical trials market: Study Design segment dashboard
  • Fig. 22 India clinical trials market: Study Design market share analysis, 2024 & 2030
  • Fig. 23 Interventional trials market, 2018 - 2030 (USD Million)
  • Fig. 24 Observational trials market, 2018 - 2030 (USD Million)
  • Fig. 25 Expanded access trials market, 2018 - 2030 (USD Million)
  • Fig. 26 India clinical trials market: Indication segment dashboard
  • Fig. 27 India clinical trials market: Indication market share analysis, 2024 & 2030
  • Fig. 28 Autoimmune/inflammation market, 2018 - 2030 (USD Million)
  • Fig. 29 Rheumatoid arthritis market, 2018 - 2030 (USD Million)
  • Fig. 30 Multiple sclerosis market, 2018 - 2030 (USD Million)
  • Fig. 31 Osteoarthritis market, 2018 - 2030 (USD Million)
  • Fig. 32 Irritable bowel syndrome (IBS) market, 2018 - 2030 (USD Million)
  • Fig. 33 Others market, 2018 - 2030 (USD Million)
  • Fig. 34 Pain management market, 2018 - 2030 (USD Million)
  • Fig. 35 Chronic pain market, 2018 - 2030 (USD Million)
  • Fig. 36 Acute pain market, 2018 - 2030 (USD Million)
  • Fig. 37 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 38 Blood cancer market, 2018 - 2030 (USD Million)
  • Fig. 39 Solid tumors market, 2018 - 2030 (USD Million)
  • Fig. 40 Other market, 2018 - 2030 (USD Million)
  • Fig. 41 CNS conditions market, 2018 - 2030 (USD Million)
  • Fig. 42 Epilepsy market, 2018 - 2030 (USD Million)
  • Fig. 43 Parkinson's disease (PD) market, 2018 - 2030 (USD Million)
  • Fig. 44 Huntington's disease market, 2018 - 2030 (USD Million)
  • Fig. 45 Stroke market, 2018 - 2030 (USD Million)
  • Fig. 46 Traumatic brain injury (TBI) market, 2018 - 2030 (USD Million)
  • Fig. 47 Amyotrophic lateral sclerosis (ALS) market, 2018 - 2030 (USD Million)
  • Fig. 48 Muscle regeneration market, 2018 - 2030 (USD Million)
  • Fig. 49 Others market, 2018 - 2030 (USD Million)
  • Fig. 50 Diabetes market, 2018 - 2030 (USD Million)
  • Fig. 51 Obesity market, 2018 - 2030 (USD Million)
  • Fig. 52 Cardiovascular market, 2018 - 2030 (USD Million)
  • Fig. 53 Others market, 2018 - 2030 (USD Million)
  • Fig. 54 India clinical trials market: Service Type segment dashboard
  • Fig. 55 India clinical trials market: Service Type market share analysis, 2024 & 2030
  • Fig. 56 Protocol designing market, 2018 - 2030 (USD Million)
  • Fig. 57 Site identification market, 2018 - 2030 (USD Million)
  • Fig. 58 Patient recruitment market, 2018 - 2030 (USD Million)
  • Fig. 59 Laboratory services market, 2018 - 2030 (USD Million)
  • Fig. 60 Bioanalytical testing services market, 2018 - 2030 (USD Million)
  • Fig. 61 Clinical trial data management services market, 2018 - 2030 (USD Million)
  • Fig. 62 Others market, 2018 - 2030 (USD Million)
  • Fig. 63 India clinical trials market: Sponsor segment dashboard
  • Fig. 64 India clinical trials market: Sponsor market share analysis, 2024 & 2030
  • Fig. 65 Pharmaceutical & biopharmaceutical companies market, 2018 - 2030 (USD Million)
  • Fig. 66 Medical device companies market, 2018 - 2030 (USD Million)
  • Fig. 67 Others market, 2018 - 2030 (USD Million)
  • Fig. 68 Company categorization
  • Fig. 69 Company market position analysis
  • Fig. 70 Strategic framework
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!